Tilray Brands Q2 FY2026 revenue record $218M; net cash $30M; reaffirms EBITDA guidance

Tilray Brands, Inc.

2026-Q2 EPS reported -$0.42 revenue$427,008,000

Net revenue $218M, a record quarterly; international medical cannabis revenue increased 36% YoY.
Ended quarter with $292M cash and marketable securities; net cash position of approximately $30M.
Canadian adult-use cannabis revenue grew 6% YoY; Tilray Pharma achieved record quarterly revenue.
Reaffirmed full-year adjusted EBITDA guidance; Chairman cites disciplined execution and long-term value.
U.S. federal cannabis rescheduling expected to unlock new market opportunity for Tilray Medical expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.